Vikas P, Borcherding N, Chennamadhavuni A, Garje R. Therapeutic potential of mixing PARP inhibitor and immunotherapy in strong tumors. Entrance Oncol. 2020;10:570.
Rudolph J, Jung Okay, Luger Okay. Inhibitors of PARP: quantity crunching and construction gazing. Proc Natl Acad Sci USA. 2022;119:e2121979119.
Rose M, Burgess JT, O’Byrne Okay, Richard DJ, Bolderson E. PARP inhibitors: scientific relevance, mechanisms of motion and tumor resistance. Entrance Cell Dev Biol. 2020;8:564601.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as upkeep remedy in sufferers with platinum-sensitive, relapsed ovarian most cancers and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, part 3 trial. Lancet Oncol. 2017;18:1274–84.
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib upkeep remedy in platinum-sensitive, recurrent ovarian most cancers. New Engl J Med. 2016;375:2154–64.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib upkeep therapy for recurrent ovarian carcinoma after response to platinum remedy (ARIEL3): a randomised, double-blind, placebo-controlled, part 3 trial. Lancet. 2017;390:1949–61.
Moore Okay, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Upkeep olaparib in sufferers with newly recognized superior ovarian most cancers. New Engl J Med. 2018;379:2495–505.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line upkeep in ovarian most cancers. New Engl J Med. 2019;381:2416–28.
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in sufferers with newly recognized superior ovarian most cancers. New Engl J Med. 2019;381:2391–402.
Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast most cancers in sufferers with a germline BRCA mutation. New Engl J Med. 2017;377:523–33.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee Okay-H, et al. Talazoparib in sufferers with superior breast most cancers and a germline BRCA mutation. New Engl J Med. 2018;379:753–63.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. OlympiA Medical Trial Steering Committee and Investigators. Adjuvant olaparib for sufferers with BRCA1- or BRCA2-mutated breast most cancers. New Engl J Med. 2021;384:2394–405.
Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in most cancers. Nat Rev Most cancers. 2021;21:345–59.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in superior triple-negative breast most cancers. New Engl J Med. 2018;379:2108–21.
Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-paclitaxel for unresectable regionally superior, or metastatic triple-negative breast most cancers: IMpassion130 remaining total survival evaluation. Ann Oncol. 2021;32:983–93.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof M, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for beforehand untreated regionally recurrent inoperable or metastatic triple-negative breast most cancers (KEYNOTE-355): a randomised, placebo-controlled, double-blind, part 3 scientific trial. Lancet. 2020;396:1817–28.
Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy in superior triple-negative breast most cancers. New Engl J Med. 2022;387:217–26.
Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab together with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in sufferers with early-stage triple-negative breast most cancers (IMpassion031): a randomised, double-blind, part 3 trial. Lancet. 2020;396:1090–100.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. KEYNOTE-522 Investigators. Occasion-free survival with pembrolizumab in early triple-negative breast most cancers. New Engl J Med. 2022;386:556–67.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast most cancers. New Engl J Med. 2020;382:810–21.
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, et al. Atezolizumab, bevacizumab, and chemotherapy for newly recognized stage III or IV ovarian most cancers: placebo-controlled randomized part III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021;39:1842–55.
Monk BJ, Colombo N, Oza AM, Fujiwara Okay, Birrer MJ, Randall L, et al. Chemotherapy with or with out avelumab adopted by avelumab upkeep versus chemotherapy alone in sufferers with beforehand untreated epithelial ovarian most cancers (JAVELIN Ovarian 100): an open-label, randomised, part 3 trial. Lancet Oncol. 2021;22:1275–89.
Pujade-Lauraine E, Fujiwara Okay, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard I-L, et al. Avelumab alone or together with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian most cancers (JAVELIN Ovarian 200): an open-label, three-arm, randomised, part 3 research. Lancet Oncol. 2021;22:1034–46.
Kurtz J-E, Pujade-Lauraine E, Oaknin A, Belin L, Leitner Okay, Cibula D, et al. ATALANTE/ENGOT-ov29 Investigators. Atezolizumab mixed with bevacizumab and platinum-based remedy for platinum-sensitive ovarian most cancers: placebo-controlled randomized part III ATALANTE/ENGOT-ov29 trial. J Clin Oncol. 2023;41:4768–78.
Hamanishi J, Takeshima N, Katsumata N, Ushijima Okay, Kimura T, Takeuchi S, et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for sufferers with platinum-resistant ovarian most cancers: open-label, randomized trial in Japan (NINJA). J Clin Oncol. 2021;39:3671–81.
Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, et al. The synergistic impact of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol. 2021;15:1179554921996288.
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian most cancers: evolution of administration within the period of precision drugs. CA Most cancers J Clin. 2019;69:280–304.
Yang C, Xia B-R, Zhang Z-C, Zhang Y-J, Lou G, Jin W-L. Immunotherapy for ovarian most cancers: adjuvant, mixture, and neoadjuvant. Entrance Immunol. 2020;11:577869.
Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade impartial of BRCAness. Most cancers Res. 2019;79:311–9.
Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M-Okay, Hsu J-M, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Most cancers Res. 2017;23:3711–20.
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, et al. The forefront of ovarian most cancers remedy: replace on PARP inhibitors. Ann Oncol. 2020;31:1148–59.
Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Affiliation and prognostic significance of BRCA1/2-mutation standing with neoantigen load, variety of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in excessive grade serous ovarian most cancers. Oncotarget. 2016;7:13587–98.
Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, et al. Affect of genomic panorama on most cancers immunotherapy for newly recognized ovarian most cancers: biomarker analyses from the IMagyn050 randomized scientific trial. Clin Most cancers Res. 2023;29:1698–707.
Tsao MS, Kerr KM, Kockx M, Beasley M-B, Borczuk AC, Botling J, et al. PD-L1 immunohistochemistry comparability research in real-life scientific samples: outcomes of blueprint part 2 mission. J Thorac Oncol. 2018;13:1302–11.
Ung C, Kockx MM. Challenges and views of immunotherapy biomarkers and the HistoOncoImmune™ methodology. Exp Rev Summary Med Drug Dev. 2016;1:9–24.
Coleman RL, Swisher EM, Oza AM, Scott CL, Giordano H, Lin KK, et al. Refinement of prespecified cutoff for genomic lack of heterozygosity (LOH) in ARIEL2 half 1: a part II research of rucaparib in sufferers (pts) with excessive grade ovarian carcinoma (HGOC). J Clin Oncol. 2016;34:5540.
FoundationOne® CDx technical info. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S006C.pdf (accessed November 25, 2021).
Chalmers ZR, Connelly CF, Fabrizio D, Homosexual L, Ali SM, Ennis R, et al. Evaluation of 100,000 human most cancers genomes reveals the panorama of tumor mutational burden. Genome Med. 2017;9:34.
Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, et al. Characterization of sufferers with long-term responses to rucaparib therapy in recurrent ovarian most cancers. Gynecol Oncol. 2021;163:490–7.
Drew Y, Kaufman B, Banerjee S, Lortholary A, Hong SH, Park YH, et al. Part II research of olaparib + durvalumab (MEDIOLA): up to date ends in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian most cancers (OC). Ann Oncol 2019;30 (Suppl 5):v485 (Summary 1190PD).
Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA third, Bidziński M, et al. Olaparib versus nonplatinum chemotherapy in sufferers with platinum-sensitive relapsed ovarian most cancers and a germline BRCA1/2 mutation (SOLO3): a randomized part III trial. J Clin Oncol. 2020;38:1164–74.
Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, et al. Atezolizumab and nab-paclitaxel in superior triple-negative breast most cancers: biomarker analysis of the IMpassion130 research. J Natl Most cancers Inst. 2021;113:1005–16.
Ovarian Tumor Tissue Evaluation (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, et al. Dose-response affiliation of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian most cancers. JAMA Oncol. 2017;3:e173290.
O’Meara TA, Tolaney SM. Tumor mutational burden as a predictor of immunotherapy response in breast most cancers. Oncotarget. 2021;12:394–400.
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Lengthy-term scientific outcomes and biomarker analyses of atezolizumab remedy for sufferers with metastatic triple-negative breast most cancers: a part 1 research. JAMA Oncol. 2019;5:74–82.
Nasta F, Laudisi F, Sambucci M, Rosado MM, Pioli C. Elevated Foxp3+ regulatory T cells in poly(ADP-Ribose) polymerase-1 deficiency. J Immunol. 2010;184:3470–7.
Luo X, Nie J, Wang S, Chen Z, Chen WJ, Li D, et al. Poly(ADP-ribosyl)ation of FOXP3 protein mediated by PARP-1 protein regulates the perform of regulatory T cells. J Biol Chem. 2015;290:28675–82.
Gu W, Ge R, Zhu F, Li D, Liang R, Ge J, et al. PARP-1 inhibitor-AG14361 suppresses acute allograft rejection by way of stabilizing CD4+FoxP3+ regulatory T cells. Pathol Res Pr. 2020;216:153021.
Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. Open-label scientific trial of niraparib mixed with pembrolizumab for therapy of superior or metastatic triple-negative breast most cancers. JAMA Oncol. 2019;5:1132–40.
Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. Single-arm phases 1 and a couple of trial of niraparib together with pembrolizumab in sufferers with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5:1141–9.
Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Smart DR, et al. Avelumab plus talazoparib in sufferers with superior strong tumors: the JAVELIN PARP Medley nonrandomized managed trial. JAMA Oncol. 2023;9:40–50.
Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori Okay, Scambia G, et al. Avelumab plus talazoparib in sufferers with BRCA1/2– or ATM-altered superior strong tumors: outcomes from JAVELIN BRCA/ATM, an open-label, multicenter, part 2b, tumor-agnostic trial. JAMA Oncol. 2023;9:29–39.
Monk BJ, Coleman RL, Fujiwara Okay, Wilson MK, Oza AM, Oaknin A, et al. ATHENA (GOG-3020/ENGOT-ov45): a randomized, part III trial to judge rucaparib as monotherapy (ATHENA-MONO) and rucaparib together with nivolumab (ATHENA-COMBO) as upkeep therapy following frontline platinum-based chemotherapy in ovarian most cancers. Int J Gynecol Most cancers. 2021;31:1589–94.
Banerjee S, Imbimbo M, Roxburgh P, Kim J-W, Plummer R, Stemmer S, et al. Part II research of olaparib plus durvalumab with or with out bevacizumab (MEDIOLA): remaining evaluation of total survival in sufferers with non-germline BRCA-mutated platinum-sensitive relapsed ovarian most cancers. Ann Oncol. 2022;33(S7):S788.
